Longitudinal Analysis of Market Utilization / Pharmaceutical Sales Data Christine Lu Harvard Medical School and Harvard Pilgrim Health Care Institute WHO.

Slides:

Advertisements

Similar presentations

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.

Advertisements

Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.

Is JCAHO Accreditation Associated with Better Patient Outcomes in Rural Hospitals? Laura Morlock, PhD Bloomberg School of Public Health Johns Hopkins University.

Impact of an antidepressant adherence program in a managed care organization Kara Zivin Bambauer, PhD Stephen Soumerai, ScD Alyce Adams, PhD Fang Zhang,

Cost-sharing for Emergency Care and Unfavorable Clinical Events: Findings from the Safety And Financial Ramifications of ED Copayments (SAFE) Study AcademyHealth.

The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.

Appendices. Appendix 1: Supplementary Data Tables Trends in the Overall Health Care Market.

Minnesota Health Care Market Trends and Strategies for Cost Containment Health Care Transformation Task Force July 30, 2007 Julie Sonier Director, Health.

Yudatiningsih I.1,Sunartono H.1,SuryawatiS.2

Interrupted Time Series: What, Why and How Karen Smith An Example From Suicide Research.

Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan Relationship between Tariffs, Prices and Consumption of Interferon.

Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD.

The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented.

1 Exploration of Health Care Providers Behavior to Keep Their Revenues after Reduction of Payment Generosity --- A Case of Drug Payment in Taiwan Likwang.

Changes in Use of Antidiabetic Medications Following Price Regulations in China ( ) Christine Lu Harvard Medical School and Harvard Pilgrim Health.

REDUCING CODEINE COUGH SYRUP MEDICINE CONSUMPTION TO CONTROL CODEINE ABUSE IN THAILAND Naiyana Patcharapisarn Narcotics Control Division Food and Drug.

Authors: Rene Soria-Saucedo 1, Veronika J. Wirtz 1, Warren A. Kaplan 2 Institutions: 1 Center for Health Systems Research, National Institute of Public.

1208 Evidence on Access to and Use of Medicines to Treat Chronic Diseases from Household Surveys in Five Low and Middle Income Countries.

1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.

Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.

1 The Budget Impact of Drugs Treating Rare Diseases in Canada: A MIDAS Sales Data Analysis April 14, 2015 Oral Presentation at the 2015 CADTH.

Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:

1 Drug and Therapeutics Committee. Objectives  Discuss the use of aggregate data including defined daily dose in analyzing the consumption of medicines.

Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care Trends in the.

The Effect of Quality Improvement on Racial Disparities in Diabetes Care Thomas D. Sequist, MD MPH Alyce S. Adams, PhD Fang Zhang, MS Dennis Ross-Degnan,

Racial Differences in the Impact of HMO Coverage of Diabetes Blood Glucose Monitors on Self-Monitoring Connie A. Mah, M.S. Department of Ambulatory Care.

Longitudinal Methods for Pharmaceutical Policy Evaluation Common Analytic Approaches Michael Law The Centre for Health Services and Policy Research The.

Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.

Determinants for Healthcare Expenditure Growth Presented by LaToyia Floyd Wayne State University Fall 2013.

Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals & Hospital Admissions Stephen T Parente Roger Feldman Jon B Christianson.

TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.

1 Bluefield Health Plan: Coaching Notes. 2 Managed Care – the Facts Companies usually pay a managed care plan a monthly premium, based on the number of.

Objective The aim was to investigate the impact of purchasing medicines jointly by the JPD for the four participating parties in the first tender on the.

Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.

Longitudinal Methods for Pharmaceutical Policy Evaluation Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care WHO Collaborating.

Disparity Implications of the Eligibility Criteria for Medication Therapy Management Services among the Non-Medicare Population Junling Wang, Ph.D., Lawrence.

Gender and Access to Medicines in 15 Low- and Middle-Income Countries: Does Physician Prescribing for Men and Women Differ? Stephens, Peter (1); Ross-Degnan,

Objective The aim was to assess purchasing pharmaceuticals in the public health sector in Jordan through the joint procurement for participating parties.

Consumption of antibiotics before and after sales regulations in Chile, Colombia and Venezuela Juan Jose Herrera Patiño, Yared Santa-Ana-Tellez,, Anahi.

Project no_File reference IMS Health Baltic September 2005 Baltic pharma market 1999 – 2004 Developments, changes and possible future trends.

Designing and Managing Medicines Benefits – Goals, Policy Options, Ethical Considerations Anita Katharina Wagner Department of Population Medicine Harvard.

INCREASING HERBAL PRODUCT CONSUMPTION IN THAILAND DURING THE PERIOD Assoc Prof Dr Arthorn Riewpaiboon Department of Pharmaceutical Botany Faculty.

Poor Research Designs in Policy Impact Studies: “Lies, Damn Lies, and Statistics” AHRQ 2007 Annual Conference: Improving Healthcare, Improving Lives September.

1 EPI235: Epi Methods in HSR April 19, 2005 L6 Program Evaluation with Longitudinal Data 2: Basic Techniques (Dr. Schneeweiss) Basic techniques and SAS.

Rapid Penetration of COX2 Inhibitors in Non-Steroidal Antiinflammatory Drug Market: an Implication to Hospital Cost Containment Policy Supon Limwattananon,

Impacts of Direct Fee-For- Service Payment Insurance on Access and Use of Drug: An Interrupted Time Series Study on Diabetic Care Inthira Kanchanaphibool,

Accessibility to Inhaled Cortico-steroids among Adults with Chronic Asthma: AN IMPACT OF THE UNIVERSAL HEALTH CARE COVERAGE POLICY Chulaporn Limwattananon,

IMPROVING ECONOMIC PRESCRIBING IN A TEACHING HOSPITAL THROUGH AN EDUCATIONAL STRATEGY TO PROMOTE GENERIC PRESCRIBING.

Copyright © 2010 SAS Institute Inc. All rights reserved. Sense & Shape Health Care Demand Laura Squier Oct 17, 2011.

Connecticut Pharmaceutical Forum: Access, Affordability, and Better Health Tara C. F. Ryan May 17, 2016.

Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.

Allergy Drugs Markets in China Published on : Jun 2014.

Market Research Report Global and Chinese Zinc dithiophosphateIndustry, Market Research Report.

Variation in place of death from cancer: studies in South East England Elizabeth Davies, Peter Madden, Victoria Coupland, Karen Linklater, Henrik Møller.

The pharmaceutical market in Europe

Quality patients value sustainability partnership Value of generic medicines.

iHEA 9th World Congress Sydney, July 8, 2013

Integrated Research Methodology

Bruce B. Cohen, PhD Massachusetts Department of Public Health

National Trends in Per Capita Pharmaceutical Spending, 1980–2015

Bluefield Health Plan: Coaching Notes

Abstract Impact of the National Healthcare Reform on Prescribing Patterns of Promotional Targeted Drugs among Thai Physicians Layton MR*, Chadbunchachai.

Readiness Survey Results Summary

Age-standardized probability of finding undiagnosed diabetes among the US population without diagnosed diabetes aged ≥18 years by survey cycle. Age-standardized.

Abstract Decreased Inappropriate Antibiotic Use Following a Korean National Policy to Prohibit Medication Dispensing by Physicians Sylvia Park, PhD; Stephen.

A LONGITUDINAL POLICY ANALYSIS OF THE IMPACT ON PRESCRIBING PATTERNS AND MEDICATION COST OF A GENERIC DISPENSING POLICY IN A TEACHING HOSPITAL IN THAILAND.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Number of events, the crude incidence rate, and the crude and adjusted HR with 95% CI for the association between pioglitazone use and all-cause mortality.

Presentation transcript:

Longitudinal Analysis of Market Utilization / Pharmaceutical Sales Data Christine Lu Harvard Medical School and Harvard Pilgrim Health Care Institute WHO Collaborating Center in Pharmaceutical Policy ICIUM 2011 (Poster 878) WHO Collaborating Center in Pharmaceutical Policy

Acknowledgements  Co-investigators: Dennis Ross-Degnan, Anita Wagner, Bao Liu, Peter Stephens  IMS Health for providing the data  Location of work: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute  Conflict of interest: None

Overview  Background / Context  The data  Challenges  Opportunities

Background – China  Country: China Most medicines sold in hospitals (80%) Hospitals rely on profits from pharmaceutical sales to cover operating costs  Policy of interest: Medicine price regulations for antidiabetic products Set product’s maximum retail price

Study aim To examine the effects of two targeted price regulations on purchasing of insulin and oral hypoglycemics in Chinese hospitals Dec 2001 Dec 2006

IMS data  Longitudinal, quarterly data  Volume data: standard units sold (e.g. one tablet) Individual product-level, can be rolled up to Drug level e.g. metformin Drug class level e.g. biguanides Categories: price regulated vs. non-regulated Adjust for population Calculate percentage market share

IMS data: Data elements Variable nameExample Country_ctyChina hospital Time of procurement2003 q1 Anatomical Therapeutic Class 2A10 (drugs used in diabetes) Anatomical Therapeutic Class 4A10H0 (sulphonylureas A-diabs) MoleculeGliclazide International packTablet 30mg 30 Launch date ProductDiamicron ManufacturerSERVIER-TIANJIN Licensing statusOriginal brand Further details see “IMS MIDAS Quantum Data Elements, Measures and Statistics”

Interrupted Time Series  Prior to using this method: Understanding the policy Sufficient data points before and after the time of the policy  Segmented regression: Estimate changes in level and trend (slope) post-policy Control for pre-existing level and trend Wagner AK et al. J Clin Pharm Ther 2002

Organizing data for time series plot

Organizing data for segmented regression

Some results Increase in trend of sales volume (0.18 standard units sold/1000 people/quarter) Price regulation

Summary of the study  China’s price regulations for antidiabetics were associated with: Increase in utilization of antidiabetics No meaningful change in market share of price- regulated antidiabetic products  ? Impact of price regulation on medicine costs for Patients Hospitals The system

Challenges  IMS data-related Only capture hospital data in China BUT most medicines are sold in hospitals Come from a sample of Chinese hospitals ( ≥ 100 beds) Volume data more reliable than pricing data  Non IMS data-related Relative drug prices

Opportunities  Clean, well-structured data from IMS Health  Data specifics well documented  Longitudinal data so can use ITS method  A large sample of hospitals across the country  Volume data available at the individual-product level  Small data file size manageable in MS Excel (& SAS)  Building a good collaboration